|
Mar 5
|
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
|
|
Mar 5
|
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
|
|
Mar 5
|
Q4 2023 Nektar Therapeutics Earnings Call
|
|
Mar 4
|
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 4
|
Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results
|
|
Mar 4
|
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
|
|
Mar 4
|
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
|
|
Jan 9
|
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
|
|
Dec 30
|
Following a 75% decline over last year, recent gains may please Nektar Therapeutics (NASDAQ:NKTR) institutional owners
|
|
Dec 8
|
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?
|
|
Dec 7
|
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?
|
|
Nov 8
|
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss
|
|
Nov 7
|
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
|
|
Oct 23
|
12 Best Penny Stocks to Buy Under $1
|
|
Sep 9
|
Will Nektar Therapeutics (NASDAQ:NKTR) Spend Its Cash Wisely?
|
|
Sep 7
|
Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?
|
|
Sep 6
|
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
|
|
Jul 16
|
Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the company
|